Since it is stated in the study that those novel approaches for rapid phenotypic susceptibility testing lowers the rate of incorrect empiric treatment choices, shortens the length of hospital stay and reduces patient mortality, are these commercial developments easy to manipulate? Also, are they now offered in all clinical microbiology labs (worldwide)?